NuCana plc
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.6M
- Price
- $1.59
- % Change (Daily % change from the live per-ticker quote feed.)
- +7.43%
- Volume
- 70.9K
About
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Quick stats
Shares outstanding4.2M
Computed float3.1M
Float / shares74.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001709626
Websitehttps://www.nucana.com
AI Summary
AI-generated1/5
standardbullishearnings
NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update
NuCana reported a Q2 2026 net loss of £3.1 million with cash and cash equivalents of £19.5 million, which management anticipates will fund operations into 2029.
Patient recruitment is now complete in the Phase 2 NuTide:701 expansion study evaluating NUC-7738 in combination with pembrolizumab, with final data expected later in 2026.
The company continues to evaluate additional indications for its lead assets NUC-7738 and NUC-3373 following FDA IND clearance earlier this year.